Dr Jose-Carlos Gutiérrez-Ramos is the Chief Science Officer at Danaher Corporation. He has held senior drug discovery roles at Pfizer,...
NASSAU, Bahamas and SAN FRANCISCO, Jan. 9, 2025 /PRNewswire/ -- Roivios, a clinical-stage medical device company, and Caresyntax, a global...
JERSEY CITY, N.J., Jan. 9, 2025 /PRNewswire/ -- Outcomes Matter Innovations, LLC ("OMI") today announced a co-development agreement with Regional...
Despite high borrowing costs and extended hold times in 2024, dealmaking roared ahead for healthcare private equity with a heavy...
Calgary, Alberta--(Newsfile Corp. - January 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) is pleased to announce...
Offers an end-to-end platform for patient recruitment, data management, Biostatistics and regulatory submission FREMONT, CALIFORNIA / ACCESSWIRE / January 9,...
LONDON, GB / ACCESSWIRE / January 9, 2025 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that it...
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025...
A 4-week treatment with IMG-007 resulted in a mean reduction in eczema area and severity index (EASI) of 77% and...
Cannabix Technologies Inc. Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge technology VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE)...
Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A...
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE...
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health...
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment...
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial...
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the...
Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA) Manuscript focused on role...
Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered...